医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2014年
11期
537-537
,共1页
新型口服抗凝药%房颤%脑卒中%华法林
新型口服抗凝藥%房顫%腦卒中%華法林
신형구복항응약%방전%뇌졸중%화법림
New oral anticoagulants%Atrial fibril ation%Stroke%Warfarin%Bleeding
四种新型口服抗凝药院达比加群、利伐沙班、阿哌沙班、依度沙班已经被四大临床试验证明较华法林具有更好的降低房颤患者脑卒中风险的效果和更小的出血风险。其中除依度沙班外，另三种抗凝药均已通过FDA认证。本文就新型口服抗凝药用于降低房颤患者脑卒中风险的研究进展作一综述。
四種新型口服抗凝藥院達比加群、利伐沙班、阿哌沙班、依度沙班已經被四大臨床試驗證明較華法林具有更好的降低房顫患者腦卒中風險的效果和更小的齣血風險。其中除依度沙班外，另三種抗凝藥均已通過FDA認證。本文就新型口服抗凝藥用于降低房顫患者腦卒中風險的研究進展作一綜述。
사충신형구복항응약원체비가군、리벌사반、아고사반、의도사반이경피사대림상시험증명교화법림구유경호적강저방전환자뇌졸중풍험적효과화경소적출혈풍험。기중제의도사반외，령삼충항응약균이통과FDA인증。본문취신형구복항응약용우강저방전환자뇌졸중풍험적연구진전작일종술。
New oral anticoagulants,including Dabigatran,Apixaban、Rivaroxaban and Edoxaban have been successful proved by four trials including ER-LY、ROCKER、AFARISTOTLE and AF-TIMI 48 as more ef ective drugs to reduce risk of stroke in patients with artrial fibril ation compared with warfarin,and less risk of bleeding. Recent research progress of new oral anticoagulants to reduce risk of stroke in patients with atrial fibril ation are reviewd.
